Peptides
Last Updated
Jun 9, 2026
Table of contents
Weight loss is one of the few areas of medicine where the science genuinely changed under our feet. A class of injectable peptides now produces results that diet and exercise alone rarely match. The catch is that "peptides for weight loss" lumps together two very different things, and only one of them has the evidence to back the headlines.
On one side are the GLP-1 medicines, semaglutide and tirzepatide, which are FDA-approved, prescription, and backed by large clinical trials. On the other side are the growth-hormone peptides, CJC-1295, ipamorelin, and the rest, which can shift body composition at the margins but have thin direct evidence for weight loss, and several of which are not even legally available right now. This guide ranks all seven honestly, tells you which category each belongs to, and shows where they fit into a plan that is actually monitored rather than mailed out and forgotten.
The numbers
What you are choosing between.
Set expectations first
Two categories, not one.
The single most useful thing to understand here is that these seven peptides split into two groups that do not belong in the same sentence. The GLP-1 drugs work on gut-hormone signaling that controls appetite and fullness, and the trials behind them are large and rigorous. Average weight loss runs from roughly fifteen percent of body weight with semaglutide to the low twenties with tirzepatide. That is a genuinely different magnitude from anything that came before.
The growth-hormone peptides work by nudging your own growth hormone up. That can support fat metabolism, recovery, and lean mass at the edges, but the controlled evidence that they cause meaningful weight loss in healthy adults is limited, and they are better thought of as body-composition tools than weight-loss drugs. Several of them are also injectables sitting behind the FDA advisory review scheduled for July 2026, so they are not legally compounded right now. Keep that split in mind as you read the rankings.
The honest landscape
Evidence vs. what you can get.
Weight-loss peptides plotted by how strong the direct evidence is against how accessible they are right now. The GLP-1 drugs sit top right: strong evidence and FDA-approved. Tesamorelin is approved but targets visceral fat rather than the scale. The growth-hormone peptides cluster bottom left, where the evidence is thin and most are pending the July 2026 review.
At a glance
Seven peptides, ranked honestly.
| Rank | Peptide | Class | What it does | Evidence | Availability |
|---|---|---|---|---|---|
| 1 | Tirzepatide GLP-1 + GIP | Incretin drug | Appetite control, largest weight loss | Strong | Available (Rx) |
| 2 | Semaglutide GLP-1 | Incretin drug | Appetite control, proven weight loss | Strong | Available (Rx) |
| 3 | Tesamorelin GHRH analog | GH-axis | Targets visceral fat specifically | Moderate | Available (Rx) |
| 4 | CJC-1295 GHRH analog | GH-axis | Body composition and recovery | Limited | Pending Jul 2026 |
| 5 | Ipamorelin GHRP, selective | GH-axis | Gentle GH rise, no appetite spike | Limited | Pending Jul 2026 |
| 6 | GHRP-2 GHRP, potent | GH-axis | Strong GH rise, raises appetite | Limited | Research only |
| 7 | AOD-9604 HGH fragment | GH fragment | Fat metabolism, weak human results | Emerging | Pending Jul 2026 |
Ranking reflects the balance of weight-loss evidence, mechanism, and how realistically you can access each one today. The gap between the top two and the rest is large and deliberate.
In depth
The peptides, one by one.
Tirzepatide
Tirzepatide is a once-weekly injection that activates two gut-hormone receptors, GLP-1 and GIP, which together blunt appetite, slow stomach emptying, and improve how the body handles insulin. In large trials it produced the biggest weight loss of any drug in this category, averaging in the high teens to low twenties as a percentage of body weight at the higher doses over about seventy-two weeks, with better muscle preservation than dieting alone. It is FDA-approved for both weight management and type 2 diabetes.
Semaglutide
Semaglutide is the once-weekly GLP-1 injection that brought this category into the mainstream. It mimics a gut hormone that increases fullness and reduces food intake, and in its landmark trials it produced average weight loss around fifteen percent of body weight over roughly sixty-eight weeks, with cardiovascular benefits documented separately. Like tirzepatide, it is FDA-approved for weight management and type 2 diabetes.
Tesamorelin
Tesamorelin is a daily injection that stimulates the body's own growth hormone, and it is FDA-approved specifically to reduce excess visceral fat in people with HIV-associated lipodystrophy. Its strength is targeting the deep abdominal fat tied to metabolic risk rather than driving a large drop on the scale. Outside that approved use it is prescribed off-label, and the general-population weight-loss evidence is more limited than its visceral-fat data.
CJC-1295
CJC-1295 is a long-acting analog of growth-hormone-releasing hormone that prompts the pituitary to release more growth hormone, often stacked with ipamorelin. The body-composition logic is more fat oxidation plus better recovery and sleep. The direct, controlled weight-loss evidence in healthy adults is limited, and it is better understood as a recovery and body-composition tool than a weight-loss drug.
Ipamorelin
Ipamorelin is a selective growth-hormone-releasing peptide valued because it raises growth hormone without the appetite spike or cortisol bump seen with stronger secretagogues, which is why it is usually paired with CJC-1295. As with CJC-1295, the honest case is body composition and recovery rather than meaningful scale weight, and the controlled weight-loss data is thin.
GHRP-2
GHRP-2 is a potent growth-hormone secretagogue. It reliably raises growth hormone, but it also tends to increase appetite, which works directly against a weight-loss goal, and it can raise cortisol. There is little controlled evidence supporting it as a weight-loss agent specifically.
AOD-9604
AOD-9604 is a fragment of human growth hormone designed to capture its fat-burning signal without the growth effects. The idea is appealing, but the clinical reality has been underwhelming: the most-cited human trial did not show meaningful weight loss versus placebo. The mechanism is interesting, the human results are not.
The honest answer
Do peptides actually cause weight loss?
It depends entirely on which peptide. The GLP-1 medicines, semaglutide and tirzepatide, genuinely drive large, well-documented weight loss in clinical trials, on the order of fifteen to twenty-plus percent of body weight, which is why they have reshaped obesity medicine. They are prescription drugs with real side effects and eligibility criteria, not supplements.
The growth-hormone peptides are a different story. They can nudge body composition by raising growth hormone, but the direct, controlled evidence that they produce meaningful weight loss is limited, and several are not legally available right now. If your goal is weight loss, the honest hierarchy puts the GLP-1 drugs first, by a wide margin, and treats the rest as supporting tools at best.
The part that actually matters
The drug is one input. The monitoring is the product.
A GLP-1 prescription is the start of the work, not the end of it. Done well, it is titrated to your response, paired with enough protein and resistance training to protect muscle, and tracked against labs that show whether your metabolic health is genuinely improving, fasting glucose and insulin, HbA1c, lipids, and liver markers, not just the number on the scale. Done poorly, it is a script mailed out with no follow-up and no idea whether you are losing fat or muscle.
OneTwenty's membership is built for the first version. Quarterly comprehensive panels, continuous data from your connected devices, and an AI coaching layer that reads it together, with treatment, where it is appropriate, handled and titrated by independent licensed providers against your actual numbers. The medication is one input. The measurement around it is what turns a weekly injection into a result you can keep.
How to approach it
A sensible way to start.
Start with a real evaluation
Weight-loss medicine is medical care, not a cosmetic quick fix. That means a clinician, eligibility based on BMI and health history, and baseline labs before anything is prescribed.
If weight loss is the goal, the GLP-1s lead
The evidence gap is not subtle. Do not let growth-hormone-peptide marketing distract from the two drugs that actually move the needle.
Protect your muscle
Rapid weight loss costs lean mass if you let it. Adequate protein and resistance training are not optional add-ons, they are part of the treatment.
Be skeptical of injectables sold as available now
The compounded growth-hormone peptides are pending the July 2026 review, and research-grade GHRP-2 is not legitimate clinical supply. Anyone selling them as a ready weight-loss fix is ahead of the evidence and the rules.
Monitor, do not just dose
Track metabolic labs and body composition, not only the scale. The point is losing fat and improving health markers, which a scale alone cannot tell you.
Measure, treat, track
Make the injection part of a plan, not the whole plan.
OneTwenty launches in June 2026 with comprehensive testing, quarterly panels, connected device data, and clinician-supervised care, so if a GLP-1 is right for you it is titrated and tracked against your real metabolic markers rather than mailed out and forgotten. Join the beta for early access.
Join the betaComprehensive testing · quarterly panels · clinician-supervised · $499/yr
Common questions
Weight-loss peptides, answered.
Do peptides actually work for weight loss?
The GLP-1 peptides, semaglutide and tirzepatide, do, with large weight loss documented in clinical trials. The growth-hormone peptides have limited direct evidence for weight loss and are better described as body-composition tools. If weight loss is the goal, the GLP-1 drugs lead by a wide margin.
What is the difference between semaglutide and tirzepatide?
Semaglutide activates one gut-hormone receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP, and in trials it generally produced larger weight loss. Both are once-weekly prescription injections, FDA-approved, and work by reducing appetite and food intake.
Are growth-hormone peptides like CJC-1295 good for fat loss?
They can support fat metabolism and recovery at the margins by raising growth hormone, but the controlled weight-loss evidence is limited, and they are not a substitute for the GLP-1 drugs. Most of the injectable ones are also pending the July 2026 FDA review, so they are not legally compounded right now.
Are weight-loss peptides safe?
The GLP-1 drugs have well-characterized side effects, mostly gastrointestinal, and eligibility criteria, so they need a licensed clinician. The growth-hormone peptides are less studied for this use. Either way, this is medical care that should be supervised, with baseline labs and follow-up.
Are peptides like CJC-1295 or AOD-9604 legal right now?
Both are among the compounded peptides awaiting the FDA advisory review scheduled for July 23, 2026. Until that review and the guidance behind it publish, they are not legally compounded or dispensed. Semaglutide and tirzepatide are different: they are FDA-approved prescription medicines obtained through a licensed provider.
OneTwenty is a health technology company, not a medical provider, pharmacy, or laboratory. Clinical services are delivered by independent licensed providers, and OneTwenty does not prescribe medication. This article is educational and is not medical advice. Semaglutide, tirzepatide, and tesamorelin are prescription medicines with eligibility criteria and possible side effects, and they should only be used under the care of a licensed clinician. Talk to a qualified clinician before starting any peptide or weight-loss treatment, especially if you are pregnant, breastfeeding, or managing a health condition.
Lifelong Optimization
Not your average
Checkup
Every life stage brings new biological demands. Tracking the right metrics at the right time helps you adapt, optimize performance, and extend both lifespan and healthspan.
Traditional
Manual Data Processing
Guesswork Trend Detection
Slow Campaign Setup
Multiple Tools, Multiple Logins
Reactive Decision-Making
Manual Reporting
Delayed Results
High Error Risk
Automated Data Sync
Real-Time Trend Insights
Instant AI Optimization
All-in-One Platform
Proactive AI-Driven Strategies
Auto-Generated Reports
Instant Performance Updates
AI Precision
Frequently Asked Questions
Clarity before
you commit
Answers on setup, scale, and support to remove blockers.
